What is the long-term trend for Janux Therapeutics's deferred revenue, net of current portion?

Over 4 years (2020 to 2025), Janux Therapeutics's deferred revenue, net of current portion has grown at a -100.0% compound annual growth rate (CAGR), from $6.05M to $0.

Janux Therapeutics JANX Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Regeneron PharmaceuticalsREGN

$225.1M+6.3%

Arcus BiosciencesRCUS

——

Other financials

Income statement

See full

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

See full

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

See full

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

See full

Market cap$889.15M-36.3%

Enterprise value$858.89M-36.2%

P/S64.8×-84.8×

Profitability

See full

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

See full

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Janux Therapeutics's deferred revenue, net of current portion?: Janux Therapeutics (JANX) reported deferred revenue, net of current portion of $8.68M in Q1 2026.
What is the long-term trend for Janux Therapeutics's deferred revenue, net of current portion?: Over 4 years (2020 to 2025), Janux Therapeutics's deferred revenue, net of current portion has grown at a -100.0% compound annual growth rate (CAGR), from $6.05M to $0.